Savara Inc (SVRA) — 10-Q Filings

10-Q Filings (6)

• Savara's Net Loss Widens to $86.6M Amid Soaring R&D, G&A Costs — Nov 12, 2025 Risk: high
  Savara Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $86.6 million, up from $66.8 million in the same
• Savara's Q2 Loss Widens Amid Rising R&D for MOLBREEVI — Aug 13, 2025 Risk: high
  Savara Inc. reported a net loss of $30.4 million for the three months ended June 30, 2025, an increase from a net loss of $22.2 million for the same period in 2
• Savara Inc. Files Q1 2025 10-Q Report — May 13, 2025 Risk: medium
  Savara Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial activities. The company, formerly known as Mast Therapeutics, Inc.,
• Savara Inc. Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Savara Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Mast Therapeutics, Inc., reported on its financial status. K
• Savara Inc. Files Q2 2024 10-Q Report — Aug 12, 2024 Risk: medium
  Savara Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Mast Therapeutics, Inc., reported on its financial position and b
• Savara Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Savara Inc (SVRA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Savara Inc. filed its 10-Q report for the quarterly period ended March 31, 2024.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX